


Corbion results 2021



- Business performance
- Outlook



• Financial performance



FY 2021 Key Points

- Organic sales growth core activities 15.0%
 - Growth driven by all three business units
- Adjusted EBITDA: €135.8M (12.7% margin), organic growth -7.6%
- Firm pricing actions started in H2 2021
- Continued high investment level to support growth
- Sustainability progress ahead of schedule



Sustainable Food Solutions

- Net Sales Organic growth of 10.8%
 - Preservation:
 - Natural preservatives continue to gain share
 - Strongest growth in new products
 - Functional Systems:
 - Higher than historical average win-rate
 - Developing in adjacent categories such as Dairy
 - Single ingredients grew substantially in beverages & confectionery
- Strong sales and innovation pipeline and increased conversion rate
- Acquisition Granolife Mexico / disposal Frozen Dough
- Application labs investment completed





Lactic Acid & Specialties

- Net Sales Organic growth of 17.0%
 - High growth in lactic acid deliveries to Total Corbion PLA joint venture
 - **Green solvents** sales grew as electronics segment more than compensated pressure in agrochemicals segment
 - Expanded production capacity completed in Gorinchem / NL
 - Medical biopolymers returned to strong growth driven by sales in drug delivery and post covid recovery in elective surgeries
 - FiberLive partially impaired: slower than expected technological developments
 - Higher growth prospects in slow release drug delivery systems







Incubator

- Net sales increased organically by 147.8%
 - Sales growth driven by AlgaPrime DHA (omega-3)
 - Aquaculture sector is becoming more receptive of using sustainable feed ingredients
 - Expanded into multiple leading aquaculture feed companies
 - Algae strain efficiency and higher volumes helped offset higher costs of materials and transport
- Path to EBITDA break-even for Omega-3 in 2022 reconfirmed





Major growth investment projects – algae fermentation & natural ferments

- Capacity expansion in Orindiuva, Brazil Algae fermentation € 10-15M
- Capacity available end 2022 to support 2023 growth
- Debottlenecking fermentation capacity
- Improving operational efficiency



- SFS production capacity for natural ferments Peoria, US € 10-15M
- Capacity available end 2022
- New Natural Ferments specialities
- Doubling fermentation capacity





Major investment project – Lactic Acid in Thailand

New lactic acid plant in Rayong, Thailand. Capex: \$ 230M

Status

- Timing on track for startup in 2023
- Construction is currently switching from civil engineering towards erecting first equipment
- Training of operators started

Challenges

- Equipment Lead times: challenging logistics
- COVID impact, general cost price increases





Sustainability progress

 Surpassed our 2025 GHG emission reduction target in 2021

Updated 2030 target in the course of 2022

 New net zero GHG emissions target in our value chain by no later than 2050







CDP Climate/supplier engagement

CDP Climate/general

CDP Water

Ecovadis

MSCI

A (was A)

A- (was A)

B (up from B-)

Platinum (improved score)

A (up from BB)



Financial performance





Profit and Loss

| | YTD | YTD | | Q4 | Q4 | |
|--------------------------------------|---------|--------|--------|-------|-------|--------|
| € million | 2021 | 2020 | % | 2021 | 2020 | % |
| Net Sales | 1,070.8 | 986.5 | 8.5% | 273.2 | 245.3 | 11.4% |
| Adjusted EBITDA | 135.8 | 158.8 | -14.5% | 22.3 | 30.4 | -26.6% |
| Adjusted EBITDA % | 12.7% | 16.1% | | 8.2% | 12.4% | |
| Adjusted Depreciation & Amortization | (64.1) | (60.3) | 6.3% | | | |
| Adjustments | 10.3 | 5.6 | 83.9% | | | |
| EBIT | 82.0 | 104.1 | -21.2% | | | |
| Financial income/expenses | (14.2) | (20.9) | -32.1% | | | |
| Result joint ventures/assoc. | 18.7 | 4.5 | 315.6% | | | |
| Taxes | (8.2) | (14.6) | -43.8% | | | |
| Result after tax | 78.3 | 73.1 | 7.1% | | | |
| EPS | 1.33 | 1.24 | 7.0% | | | |



Firm pricing actions implemented

- We expect full compensation of higher input costs
 - In aggregate, input costs in 2021 and 2022 rise by € 165M (of which € 130M in Core)
- Firm pricing actions implemented
 - H2 2021: First results of pricing actions visible
 - H1 2022: Further price increases phasing in
- Pricing contract structure more flexible
 - Majority of contracts moved from annual to quarterly pricing
 - Provides for faster price adjustments
- Pricing actions have mathematical dilutive effect on margin


Additional raw materials, energy, packaging, freight increase

| € million | 2021 vs 2020 | 2022 vs 2021 | Cumulative |
|-----------|--------------|--------------|------------|
| Core | 40 | 90 | 130 |
| Non-core | 10 | 25 | 35 |
| Total | 50 | 115 | 165 |



Sustainable Food Solutions

| € million | YTD 2021 | YTD 2020 | Q4 2021 | Q4 2020 |
|------------------------|----------|----------|---------|---------|
| Net sales | 584.2 | 545.8 | 148.6 | 140.1 |
| Organic growth | 10.8% | 6.8% | 3.1% | 11.8% |
| Adjusted EBITDA | 69.3 | 92.7 | 10.4 | 19.4 |
| Adjusted EBITDA margin | 11.9% | 17.0% | 7.0% | 13.8% |




- Net sales organic growth of 10.8%
- Adjusted EBITDA margin from 17.0% to 11.9%
 - Rapidly rising input costs not yet reflected in sales price
 - Investments in organizational capabilities
 - Q4 margin adversely impacted by temporary production outage in our lactic acid plant in the US



Lactic Acid & Specialties

| € million | YTD 2021 | YTD 2020 | Q4 2021 | Q4 2020 |
|------------------------|----------|----------|---------|---------|
| Net sales | 312.3 | 275.8 | 80.2 | 64.4 |
| Organic growth | 17.0% | 6.2% | 25.0% | 4.0% |
| Adjusted EBITDA | 60.5 | 61.0 | 12.8 | 11.1 |
| Adjusted EBITDA margin | 19.4% | 22.1% | 16.0% | 17.2% |



- Net sales organic growth of 17.0%
- Adjusted EBITDA margin from 22.1% to 19.4%
 - Rapidly rising input costs not yet reflected in sales price
 - Headcount increase related to lactic acid capacity expansion and biopolymers



Incubator

| € million | YTD 2021 | YTD 2020 | Q4 2021 | Q4 2020 |
|------------------------|----------|----------|---------|---------|
| Net sales | 30.7 | 13.4 | 7.8 | 4.5 |
| Organic growth | 147.8% | 33.9% | 68.9% | 162.5% |
| Adjusted EBITDA | (11.7) | (18.4) | (2.4) | (5.2) |
| Adjusted EBITDA margin | -38.1% | -137.3% | -30.8% | -115.6% |



- Net sales organic growth of 147.8%
 - Sales growth driven by AlgaPrime DHA (omega-3)
- Adjusted EBITDA loss declined from € -18.4 million to € -11.7 million



Total Corbion PLA joint venture

| € million * | YTD 2021 | YTD 2020 | Q4 202 | 1 Q4 2020 |
|---------------|----------|----------|--------|-----------|
| Net sales | 159.8 | 129.3 | 47. | 2 33.2 |
| EBITDA | 54.6 | 47.7 | 14. | 8 12.7 |
| EBITDA margin | 34.2% | 36.9% | 31.49 | % 38.3% |

^{*}Results on100% basis. Corbion owns 50% of Total Corbion PLA joint venture

- Net Sales organic growth of 28.1% through combination of price and volume growth
- EBITDA margin lower as higher input and freight costs and investments in organization offset positive operational leverage






Non-core activities

| € million | YTD 2021 | YTD 2020 | Q4 2021 | Q4 2020 |
|------------------------|----------|----------|---------|---------|
| Net sales | 143.6 | 151.5 | 36.6 | 36.3 |
| Organic growth | 12.8% | -1.1% | 12.9% | 1.1% |
| Adjusted EBITDA | 17.7 | 23.5 | 1.5 | 5.1 |
| Adjusted EBITDA margin | 12.3% | 15.5% | 4.1% | 14.0% |

- Net Sales organic growth of 12.8% in Emulsifiers through market share gains
- Emulsifiers is now sole remaining active business in non-core activities
 - Frozen dough activities sold in January 2021
- Margin pressure in Q4 due to rising input costs (mostly soybean oil) not yet reflected in price



Net debt bridge 2021




• Divestment (in)tangible assets

- Plot of land Breda, NL (Jan '21)
- Frozen dough activities (Jan '21)
- Covenant net debt/covenant EBITDA increased from 2.1x to 2.6x
 - covenant net debt/covenant EBITDA is 3.75x



Free Cash Flow



• Significant investment program

• New lactic acid plant in Thailand

Lower operating cashflow

- Increased working capital
 - inflationary input costs
 - safety stock buildup
- Reduced EBITDA



Outlook 2022

- Net Sales Organic growth core activities 15-20%
- Reach EBITDA break-even in the AlgaPrime DHA business (algae-derived omega-3)
- Input costs: Successfully increased prices to fully compensate for additional input costs
 - Input cost expected to continue to rise; might require additional pricing actions
- Adjusted EBITDA margin core activities: 12-15%
- Capital expenditures: € 200 230 million



Annex



Net sales and Adjusted EBITDA: YTD/Q4 2021

| € million | YTD 2021 | YTD 2020 | Q4 2021 | Q4 2020 | Growth YTD |
|------------------------------|----------|----------|---------|---------|------------|
| Net sales | | | | | |
| Core | 927.2 | 835.0 | 236.6 | 209.0 | 11.0% |
| - Sustainable Food Solutions | 584.2 | 545.8 | 148.6 | 140.1 | 7.0% |
| - Lactic Acid & Specialties | 312.3 | 275.8 | 80.2 | 64.4 | 13.2% |
| - Incubator | 30.7 | 13.4 | 7.8 | 4.5 | 129.1% |
| Non-core | 143.6 | 151.5 | 36.6 | 36.3 | -5.2% |
| Total Net Sales | 1,070.8 | 986.5 | 273.2 | 245.3 | 8.5% |
| Adjusted EBITDA | | | | | |
| Core | 118.1 | 135.3 | 20.8 | 25.3 | -12.7% |
| - Sustainable Food Solutions | 69.3 | 92.7 | 10.4 | 19.4 | -25.2% |
| - Lactic Acid & Specialties | 60.5 | 61.0 | 12.8 | 11.1 | -0.8% |
| - Incubator | (11.7) | (18.4) | (2.4) | (5.2) | 36.4% |
| Non-core | 17.7 | 23.5 | 1.5 | 5.1 | -24.7% |
| Total Adjusted EBITDA | 135.8 | 158.8 | 22.3 | 30.4 | -14.5% |




Sales Growth per segment in YTD/Q4 2021

| Net sales | Volume | Price/Mix | Organic | Currency | Acquisitions/ (Divestments) | Total growth |
|------------------------------|--------|-----------|---------|----------|--------------------------------|--------------|
| YTD 2021 vs YTD 2020 | | | | | | |
| Core | 9.6% | 4.9% | 15.0% | -4.1% | 0.1% | 11.0% |
| - Sustainable Food Solutions | 4.5% | 6.0% | 10.8% | -3.9% | 0.1% | 7.0% |
| - Lactic Acid & Specialties | 14.4% | 2.3% | 17.0% | -3.8% | 0.0% | 13.2% |
| - Incubator | 109.7% | 18.2% | 147.8% | -18.7% | 0.0% | 129.1% |
| Non-core | 5.5% | 6.9% | 12.8% | -4.0% | -14.0% | -5.2% |
| Total | 9.0% | 5.2% | 14.7% | -4.1% | -2.1% | 8.5% |
| Q4 2021 vs Q4 2020 | | | | | | |
| Core | -1.3% | 12.8% | 11.3% | 2.0% | -0.1% | 13.2% |
| - Sustainable Food Solutions | -6.2% | 10.0% | 3.1% | 3.1% | -0.1% | 6.1% |
| - Lactic Acid & Specialties | 5.3% | 18.8% | 25.0% | -0.5% | 0.0% | 24.5% |
| - Incubator | 47.6% | 14.4% | 68.9% | 4.4% | 0.0% | 73.3% |
| Non-core | 3.0% | 9.6% | 12.9% | 5.0% | -17.1% | 0.8% |
| Total | -0.6% | 12.2% | 11.6% | 2.4% | -2.6% | 11.4% |




Core Adjusted EBITDA bridge YTD 2021



- Volume growth in all 3 business segments
- Pricing and mix
 - Negative mix as lactic acid sales to PLA JV increased
 - Price increases partly offsetting input cost inflation
- Fixed Costs increase mostly due to organizational investments (employee count +10% y/y), salary inflation, and indexation




Core Adjusted EBITDA bridge Q4 2021





Investments

Investments



• Total capex 2021 € 165M

- Recurring capex € 100M (including expansion projects)
- New Lactic Acid plant (Thailand) € 64.9M

• Recurring capex includes

- Lactic acid debottlenecking € 30.6M
- ERP investment € 7.3M

Acquisitions


• Granotec Mexico € 11.1M (June '21)

• Capex outlook 2022

- 2022 estimated capex € 200-230M
- New Lactic Acid plant (Thailand), algae fermentation plant capacity (Brazil), natural ferments plant capacity (US)



Working capital (days)




- Increased Inventory days mainly caused by inflationary input costs and safety stock build up
- Q4 one-off temporary impact due to intercompany sales elimination





Investor relations







+31 20 590 6293